KRAS and neoplasm: Retrospective analyses have shown that bevacizumab in combination with irinotecan/5-fluorouracil (5-FU)/leucovorin chemotherapy provides a significant clinical benefit for patients with mutant (MT) and wild-type (WT) KRAS tumours [30], [31].